Penehyclidine Hydrochloride Veterinary Grade API is supplied as a white to off-white crystalline powder with a stated assay acceptance range of 98.0%–102.0% on the dried basis when quantified by HPLC-UV. The hydrochloride salt is selected over the free base for aqueous solubility across multiple veterinary dosage presentations; pH drift above 6.5 may reduce solubility by converting the salt to the free base. Manufacturer article codes distinguish general non-sterile powder grade, direct compression grade, and low-endotoxin injectable grade; each designation is tied to particle size distribution, residual solvent profile, and microbial load. The bulk API is usually packed in double low-density polyethylene liners within aluminum composite bags and sealed under nitrogen. Long-term storage for the bulk API is specified as 2–8°C or controlled room temperature, with protection from light and humidity; the exact condition depends on the grade and container closure system.

What Release Limits and Residual Solvent Controls Apply to the Veterinary API?

In the absence of a fully harmonized veterinary monograph, release testing follows a set of compendial and ICH/VICH-aligned methods. The specification includes identification by HPLC retention time and Fourier transform infrared spectroscopy, assay, related substances, water content, residual solvents, elemental impurities, and particle size. The limits for related substances are based on HPLC area percent; unspecified impurities are controlled at ≤0.10% and total impurities at ≤0.5%. Residual solvent control follows ICH Q3C/VICH GL18; Class 1 solvents are absent, and Class 2 solvents are controlled by option 1 or option 2 limits depending on batch history. For injectable grade, bacterial endotoxin content is tested by USP <85>; the typical acceptance limit is <0.50 EU/mg or product-specific.

When a compendial monograph is unavailable, a manufacturer may use an in-house specification with justification of the test methods and limits. Lot release also includes storage orientation confirmation by X-ray powder diffraction or differential scanning calorimetry where polymorphic change would alter dissolution rate or blend uniformity. The release specification includes bulk density and tapped density when the API is intended for direct compression. Bulk density 0.30–0.50 g/mL and tapped density 0.45–0.70 g/mL are typical; Carr index 20–30 indicates fair to passable flow, but exact flow behavior should be measured according to USP <1174>. If the Carr index exceeds 35, flow aids such as colloidal silicon dioxide may be required at 0.5–1.0% w/w, provided interaction with the active material is excluded.

For non-sterile oral powders, the microbial quality standard is USP <61>/<62>; for injectable solution, endotoxin and sterility testing are non-negotiable. The API should be stored in airtight, light-resistant containers with desiccant because moisture and light exposure can alter the impurity profile during extended warehousing.

When Sterile Injectable Compounding Is Specified

The low-endotoxin injectable grade is handled in an ISO 14644-1 classified area; final filling occurs at ISO Class 5 under unidirectional airflow. The solution is prepared in Water for Injection and adjusted to pH 4.5–5.5 with dilute hydrochloric acid or sodium hydroxide. Tonicity is adjusted with sodium chloride to 290–310 mOsm/kg. Terminal sterilization by autoclaving at 121°C for 15 min may be applied only where real-time and accelerated stability data confirm that assay loss and impurity formation remain within acceptance limits. Otherwise, sterile filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane followed by aseptic filling is required. The filled container is typically Type I borosilicate glass with a butyl rubber stopper and nitrogen headspace. Experimental stress studies should evaluate pH-dependent hydrolysis because tertiary amine salts can undergo free-base precipitation and hydrolytic degradation in neutral to alkaline solution.

For injectable formulations, the API is not typically sterilized as a dry powder by gamma irradiation without supporting data because radiolytic degradation may produce unidentified volatile impurities. If steam sterilization is not compatible, dry heat sterilization is generally not recommended due to thermal sensitivity and the absence of published time-temperature data for this specific veterinary configuration. Filter compatibility should be confirmed by bubble point and product integrity testing; adsorption of the active moiety onto certain media may require a saturation flush. Dissolved oxygen in the filled vial is controlled below 2.0 mg/L, and light exposure is minimized; photostability testing per ICH Q1B should determine whether amber glass is required.

Premix Homogeneity and Carryover Boundaries in Low-Dose Feed Applications

In premix and oral granule presentations, the API is first diluted by geometric dilution with spray-dried lactose or dextrose monohydrate at 1:10, then 1:100, before final mixing in a ribbon blender or double-cone blender. The mixer is operated at 60–70% fill volume for 15–20 min at moderate speed. Overfilling above 80% reduces axial mixing and can create dead zones at end plates. Blend uniformity requires stratified sampling at 10 locations, with target RSD ≤5.0% for low-dose premixes. Residual carryover in shared equipment is evaluated using maximum allowable carryover calculations; swab limits are often set below 1.0 µg/cm². Cleaning validation uses an HPLC swab method with recovery factor correction. For pig and poultry premix lines, the API should be protected from high-shear pre-milling that raises product temperature above 40°C.

Oral powders and granules for solution or suspension can be manufactured by fluid-bed top spray granulation. A low-viscosity aqueous binder such as povidone K30 is sprayed at inlet air temperature 60–70°C, product temperature 30–35°C, and spray rate 10–15 g/min/kg. Granule particle size D50 150–300 µm and bulk density 0.45–0.65 g/mL are typical starting points, but published data for this specific veterinary API configuration is limited; pilot-scale optimizations are required. Moisture content after drying is maintained below 2.0% to avoid capsule shell deformation and microbial growth. Low-shear tumble blending with a V-blender is not recommended for premixes below 0.1% w/w active content unless a pre-blend is used.

Direct Compression and Capsule Filling Require Moisture Control at the Tooling Interface

Direct compression grade is selected for tablet and capsule blends containing microcrystalline cellulose and lactose monohydrate. Before blending, the API should be passed through a 500 µm conical mill if agglomerates exceed 2 mm. Rotary tablet press compression is typically evaluated at 8–12 kN force and target hardness 6–9 kp; the API may undergo plastic deformation, so precompression force and dwell time require optimization. When ambient relative humidity exceeds 60%, pre-drying in a vacuum tray dryer at 45°C ± 5°C for 2–4 h is recommended before direct blending or dry granulation. Moisture uptake above 1.0% can reduce flowability and promote sticking to punch faces, particularly in prolonged compression runs. Tablet press speed, feeder type, and tooling surface finish should be evaluated because the material may exhibit edge picking at high press speeds.

The dissolution method for solid oral dosage forms should follow USP <711> with media selected according to the target species and formulation pH range. For quality control, USP <905> uniformity of dosage units applies with acceptance value ≤15.0. Disintegration testing per USP <701> may be used as a routine control if dissolution is not required for every batch. In capsule filling, final blend moisture is maintained below 2.0% to prevent hard gelatin shell deformation; HPMC capsules may tolerate slightly higher moisture but still require desiccated packaging.

How Does This API Differ from Atropine Sulfate and Scopolamine Hydrobromide in Formulation Development?

Penehyclidine Hydrochloride is not interchangeable with atropine sulfate or scopolamine hydrobromide on an equal-mass basis. The hydrochloride salt factor and free base content differ; dosing equivalence must be calculated from the approved veterinary product registration or prescription, not from stoichiometric salt conversion alone. In solution, the compound shares the general antimuscarinic class sensitivity to alkaline pH but may produce a different degradation fingerprint under oxidative stress. Atropine sulfate has established compendial monographs in multiple pharmacopoeias; penehyclidine hydrochloride may rely on manufacturer specifications where compendial harmonization is absent. Scopolamine hydrobromide has different central and peripheral distribution characteristics; the selection among these agents is target-species-specific and regulatory-status-dependent. Comparative stability data in target veterinary species is limited; formulators should not substitute one antimuscarinic API for another without forced degradation, dissolution, and in vivo equivalence studies.

The API should not be blended with strongly alkaline excipients such as sodium carbonate or dibasic sodium phosphate anhydrous unless the final blend pH is confirmed below 6.5 and the salt form remains intact. Contact with strong oxidizing agents should be avoided because degradation products may include N-oxide or hydroxylated species not typically quantified by the routine related substances method. Storage is prescribed in airtight, light-resistant containers with desiccant; stability testing follows ICH/VICH climatic zones, commonly 25°C/60% RH for Zone II or 30°C/65% RH for Zone IVb, with accelerated conditions at 40°C/75% RH. Freeze-thaw cycling of injectable solutions is not recommended because precipitation may occur. Bulk and finished product should not be exposed to direct sunlight for extended periods, and primary containers should remain sealed until use.